A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
- 19 Jan 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 10 Jun 2017 Biomarkers information updated